Pharmaron Beijing Files Director List with HKEX

Pharmaron Beijing Co. Ltd. has published its latest list of directors and their roles in a filing to the Hong Kong Stock Exchange. The Board is led by Dr. Lou Boliang, who serves as chairman and is also a member of the Nomination and Strategy Committees. Executive directors include Mr. Lou Xiaoqiang, a member of the Strategy Committee, and Ms. Zheng Bei, a member of the Nomination Committee. Mr. Li Shing Chung Gilbert serves as the Employee Representative Director. Non-executive directors are Mr. Li Jiaqing and Ms. Wan Xuan, both serving as members of the Strategy Committee. Independent non-executive directors include Ms. Li Lihua, chair of both the Remuneration and Appraisal Committee and the Nomination Committee, and a member of the Audit Committee; Mr. Yu Jian, chair of the Audit Committee and member of the Remuneration and Appraisal and Nomination Committees; and Prof. Tsang King Fung, a member of the Audit, Remuneration and Appraisal, and Nomination Committees. The Board comprises four committees: Audit, Remuneration and Appraisal, Nomination, and Strategy, with designated directors serving as chairpersons and members to oversee the company’s governance and strategic direction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmaron Beijing Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251218-11960674), on December 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)